Table 2: Clinical and laboratory characteristics of patients in the psoriatic arthritis (PsA) and psoriasis vulgaris (PsO) groups.

VariablePsA group
( )
PsO group
( )

Anti-MCV positivity (%)248
Level of anti-MCV (mean ± SD; U/mL)30.32 ± 82.148.71 ± 7.41
ANA positivity (%)38Not measured
RF positivity (>9 U/mL; %)11Not measured
Active psoriatic lesions in the skin10095
 PASI score (mean ± SD)5.84 ± 6.75
 Nail psoriasis (%)2843
 Scalp psoriasis (%) 7257
 Plaques on the face (%)1114
 Plaques on the upper limbs (%)6171
 Plaques on the trunk (%)3048
 Plaques on the perineum (%)157
 Plaques on the lower limbs (%)5988
Arthritic features
 DAS28 score (mean ± SD)4.51 ± 1.00
 DIP involvement (%)33
 Erosion (%)24
 Tender joint count (mean ± SD)9.78 ± 5.90
  Back (%)48
  Shoulders (%)37
  Elbows (%)15
  Wrists (%)46
  Hands (%)67
  Hips (%)17
  Knees (%)35
  Feet (%)61
 Swollen joint count (mean ± SD)2.67 ± 3.19
  Swollen shoulder (%)0
  Swollen elbow (%)2
  Swollen wrist (%)9
  Hand joints (%)43
  Swollen knee (%)11
  Feet joints (%)26

Anti-MCVs: antibodies against mutated citrullinated vimentin, ANA: anti-nuclear antibody, RF: rheumatoid factor, DIP: distal interphallangeal, PASI: psoriasis area and severity index, DAS28: disease activity score.